# Amarin Corp Plc\\uk: financial statements, quarterly AMRN · Nasdaq · CIK 897448 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/amrn.md) · [Financials](/companies/amrn/financials.md) · [Filings](/companies/amrn/filings.md) · [Insiders](/companies/amrn/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amrn/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [74.7 d](/filings/0001193125-26-085818.md) | [56.5](/filings/0000950170-25-064981.md) | [67.5](/filings/0000950170-25-099879.md) | [42.3](/filings/0001193125-25-254621.md) | [62.3 d](/filings/0001193125-26-085818.md) | [42.0](/filings/0001193125-26-188940.md) | [72.7](/filings/0001193125-26-323845.md) | [49.7](/filings/0001193125-26-435082.md) | [49.2 d](/filings/0001193125-26-085818.md) | [45.1](/filings/0001193125-26-188940.md) | [42.2](/filings/0001193125-26-323845.md) | [39.6](/filings/0001193125-26-435082.md) | | Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross profit | $m | [45.1 d](/filings/0001193125-26-085818.md) | [31.9](/filings/0000950170-25-064981.md) | [42.8](/filings/0000950170-25-099879.md) | [16.3](/filings/0001193125-25-254621.md) | [(9.6) d](/filings/0001193125-26-085818.md) | [25.1](/filings/0001193125-26-188940.md) | [50.4](/filings/0001193125-26-323845.md) | [22.2](/filings/0001193125-26-435082.md) | [23.2 d](/filings/0001193125-26-085818.md) | [17.8](/filings/0001193125-26-188940.md) | [15.0](/filings/0001193125-26-323845.md) | [16.2](/filings/0001193125-26-435082.md) | | Research and development | $m | [5.8 d](/filings/0001193125-26-085818.md) | [5.6](/filings/0000950170-25-064981.md) | [4.7](/filings/0000950170-25-099879.md) | [4.5](/filings/0001193125-25-254621.md) | [6.0 d](/filings/0001193125-26-085818.md) | [5.3](/filings/0001193125-26-188940.md) | [4.9](/filings/0001193125-26-323845.md) | [4.2](/filings/0001193125-26-435082.md) | [5.4 d](/filings/0001193125-26-085818.md) | [4.7](/filings/0001193125-26-188940.md) | [4.8](/filings/0001193125-26-323845.md) | [4.2](/filings/0001193125-26-435082.md) | | Selling, general and administrative | $m | [43.9 d](/filings/0001193125-26-085818.md) | [39.9](/filings/0000950170-25-064981.md) | [38.5](/filings/0000950170-25-099879.md) | [36.9](/filings/0001193125-25-254621.md) | [37.0 d](/filings/0001193125-26-085818.md) | [36.6](/filings/0001193125-26-188940.md) | [38.7](/filings/0001193125-26-323845.md) | [19.7](/filings/0001193125-26-435082.md) | [20.1 d](/filings/0001193125-26-085818.md) | [21.1](/filings/0001193125-26-188940.md) | [22.2](/filings/0001193125-26-323845.md) | [14.3](/filings/0001193125-26-435082.md) | | Operating income | $m | [(4.8) d](/filings/0001193125-26-085818.md) | [(13.6)](/filings/0000950170-25-064981.md) | [(0.5)](/filings/0000950170-25-099879.md) | [(25.2)](/filings/0001193125-25-254621.md) | [(52.5) d](/filings/0001193125-26-085818.md) | [(16.8)](/filings/0001193125-26-188940.md) | [(16.0)](/filings/0001193125-26-323845.md) | [(11.1)](/filings/0001193125-26-435082.md) | [(6.3) d](/filings/0001193125-26-085818.md) | [(11.3)](/filings/0001193125-26-188940.md) | [(12.0)](/filings/0001193125-26-323845.md) | [(2.4)](/filings/0001193125-26-435082.md) | | Income tax | $m | [3.3 d](/filings/0001193125-26-085818.md) | [1.3](/filings/0000950170-25-064981.md) | [1.4](/filings/0000950170-25-099879.md) | [3.6](/filings/0001193125-25-254621.md) | [(1.3) d](/filings/0001193125-26-085818.md) | [2.1](/filings/0001193125-26-188940.md) | [0.7](/filings/0001193125-26-323845.md) | [(0.4)](/filings/0001193125-26-435082.md) | [0.4 d](/filings/0001193125-26-085818.md) | [1.8](/filings/0001193125-26-188940.md) | [(0.2)](/filings/0001193125-26-323845.md) | [0.1](/filings/0001193125-26-435082.md) | | Net income | $m | [(5.8) d](/filings/0001193125-26-085818.md) | [(10.0)](/filings/0001193125-25-254621.md) | [1.5](/filings/0001193125-25-254621.md) | [(25.1)](/filings/0001193125-25-254621.md) | [(48.6) d](/filings/0001193125-26-085818.md) | [(15.7)](/filings/0001193125-26-435082.md) | [(14.1)](/filings/0001193125-26-435082.md) | [(7.7)](/filings/0001193125-26-435082.md) | [(1.2) d](/filings/0001193125-26-085818.md) | [(10.5)](/filings/0001193125-26-435082.md) | [(7.7)](/filings/0001193125-26-435082.md) | [0.2](/filings/0001193125-26-435082.md) | | Diluted EPS | $ per share | not reported | [(0.02)](/filings/0000950170-25-064981.md) | [0.00](/filings/0000950170-25-099879.md) | [(0.06)](/filings/0001193125-25-254621.md) | not reported | [(0.04)](/filings/0001193125-26-188940.md) | [(0.03)](/filings/0001193125-26-323845.md) | [(0.02)](/filings/0001193125-26-435082.md) | not reported | [(0.03)](/filings/0001193125-26-188940.md) | [(0.02)](/filings/0001193125-26-323845.md) | [0.00](/filings/0001193125-26-435082.md) | | Basic EPS | $ per share | not reported | [(0.02)](/filings/0000950170-25-064981.md) | [0.00](/filings/0000950170-25-099879.md) | [(0.06)](/filings/0001193125-25-254621.md) | not reported | [(0.04)](/filings/0001193125-26-188940.md) | [(0.03)](/filings/0001193125-26-323845.md) | [(0.02)](/filings/0001193125-26-435082.md) | not reported | [(0.03)](/filings/0001193125-26-188940.md) | [(0.02)](/filings/0001193125-26-323845.md) | [0.00](/filings/0001193125-26-435082.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: not reported - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [199](/filings/0000950170-25-037620.md) | [214](/filings/0000950170-24-050886.md) | [216](/filings/0000950170-24-088233.md) | [157](/filings/0000950170-24-118990.md) | [121](/filings/0001193125-26-085818.md) | [120](/filings/0000950170-25-064981.md) | [148](/filings/0000950170-25-099879.md) | [123](/filings/0001193125-25-254621.md) | [135](/filings/0001193125-26-435082.md) | [131](/filings/0001193125-26-188940.md) | [144](/filings/0001193125-26-323845.md) | [157](/filings/0001193125-26-435082.md) | | Current assets | $m | [725](/filings/0000950170-25-037620.md) | [688](/filings/0000950170-24-050886.md) | [702](/filings/0000950170-24-088233.md) | [650](/filings/0000950170-24-118990.md) | [595](/filings/0001193125-26-085818.md) | [573](/filings/0000950170-25-064981.md) | [607](/filings/0000950170-25-099879.md) | [628](/filings/0001193125-25-254621.md) | [650](/filings/0001193125-26-435082.md) | [626](/filings/0001193125-26-188940.md) | [603](/filings/0001193125-26-323845.md) | [613](/filings/0001193125-26-435082.md) | | Total assets | $m | [832](/filings/0000950170-25-037620.md) | [790](/filings/0000950170-24-050886.md) | [800](/filings/0000950170-24-088233.md) | [751](/filings/0000950170-24-118990.md) | [685](/filings/0001193125-26-085818.md) | [656](/filings/0000950170-25-064981.md) | [670](/filings/0000950170-25-099879.md) | [660](/filings/0001193125-25-254621.md) | [671](/filings/0001193125-26-435082.md) | [646](/filings/0001193125-26-188940.md) | [624](/filings/0001193125-26-323845.md) | [634](/filings/0001193125-26-435082.md) | | Current liabilities | $m | [259](/filings/0000950170-25-037620.md) | [224](/filings/0000950170-24-050886.md) | [231](/filings/0000950170-24-088233.md) | [202](/filings/0000950170-24-118990.md) | [180](/filings/0001193125-26-085818.md) | [162](/filings/0000950170-25-064981.md) | [186](/filings/0000950170-25-099879.md) | [182](/filings/0001193125-25-254621.md) | [194](/filings/0001193125-26-435082.md) | [180](/filings/0001193125-26-188940.md) | [164](/filings/0001193125-26-323845.md) | [175](/filings/0001193125-26-435082.md) | | Total liabilities | $m | [280](/filings/0000950170-25-037620.md) | [244](/filings/0000950170-24-050886.md) | [248](/filings/0000950170-24-088233.md) | [219](/filings/0000950170-24-118990.md) | [199](/filings/0001193125-26-085818.md) | [182](/filings/0000950170-25-064981.md) | [205](/filings/0000950170-25-099879.md) | [201](/filings/0001193125-25-254621.md) | [211](/filings/0001193125-26-435082.md) | [196](/filings/0001193125-26-188940.md) | [181](/filings/0001193125-26-323845.md) | [190](/filings/0001193125-26-435082.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [552](/filings/0001193125-26-085818.md) | [546](/filings/0001193125-25-254621.md) | [552](/filings/0001193125-25-254621.md) | [531](/filings/0001193125-25-254621.md) | [486](/filings/0001193125-26-435082.md) | [474](/filings/0001193125-26-435082.md) | [465](/filings/0001193125-26-435082.md) | [459](/filings/0001193125-26-435082.md) | [459](/filings/0001193125-26-435082.md) | [449](/filings/0001193125-26-435082.md) | [444](/filings/0001193125-26-435082.md) | [444](/filings/0001193125-26-435082.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(0.6) d](/filings/0001193125-26-085818.md) | [(12.6)](/filings/0000950170-25-064981.md) | [(2.7) d](/filings/0000950170-25-099879.md) | [(2.4) d](/filings/0001193125-25-254621.md) | [(13.3) d](/filings/0001193125-26-085818.md) | [(12.5)](/filings/0001193125-26-188940.md) | [16.6 d](/filings/0001193125-26-323845.md) | [(12.7) d](/filings/0001193125-26-435082.md) | [15.3 d](/filings/0001193125-26-085818.md) | [6.4](/filings/0001193125-26-188940.md) | [6.6 d](/filings/0001193125-26-323845.md) | [9.2 d](/filings/0001193125-26-435082.md) | | Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: not reported - Share repurchases: not reported ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [406](/filings/0000950170-24-050886.md) | [408](/filings/0000950170-24-088233.md) | [408](/filings/0000950170-24-118990.md) | [410](/filings/0000950170-25-064981.md) | [411](/filings/0000950170-25-099879.md) | [411](/filings/0001193125-25-254621.md) | [413](/filings/0001193125-26-188940.md) | [414](/filings/0001193125-26-323845.md) | [416](/filings/0001193125-26-435082.md) | [419](/filings/0001193125-26-188940.md) | [416](/filings/0001193125-26-323845.md) | [428](/filings/0001193125-26-435082.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 380,694 at 2013-02-20, from the cover of the [10-K filed 2013-02-28](/filings/0001193125-13-084191.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 28, 2026, 08:23 ET. No prices; not investment advice.